Non-randomized Medical Device Clinical Studies: A Regulatory Perspective Sep. 16, 2005 Lilly Yue, Ph.D.* CDRH, FDA, Rockville MD 20850 * No official support.
Biostatistics, part 1, Descriptive statistics: Key concepts
Early Cardiac Safety Data in Clinical Trials
Prevention of Type 2 Diabetes
Emerging treatments in Crohn’s disease and ulcerative colitis Athos Bousvaros MD MPH Boston Children’s Hospital.
Copyright © 2008, Intel Corporation. All rights reserved. Care Beyond the Hospital: Partnership for the Future: HIT, Clinical informatics and CV care Dr.
Insulin and Sensors Where are we now and where are we heading? Bruce W. Bode, MD, FACE Atlanta Diabetes Associates Atlanta, Georgia.
What Is Currently in the Pipeline & What is Ideal for an ARV-based Prevention Candidate? Carl W. Dieffenbach, Ph.D. Director, Division of AIDS, NIAID,
XELOX vs. FOLFOX4: survival and response results from XELOX-1 / NO16966, a randomized phase III trial of first-line treatment for patients with metastatic.
Proposal to the National Highway Traffic Safety Administration (NHTSA) Project Title: A Cooperative Program to Reduce Incidents of Vehicles Passing Stopped.
A Report from ASCO 2007 First-Line Metastatic Colorectal Cancer
